Historically, numerous anti-GD2 mAbs have been evaluated for clinical use in neuroblastoma cases including 3F8, humanized 3F8 (naxitamab), 14.G2a, DIN, hu14.18K322A, humanized 14.18 fused with interleukin-2, and dinutuximab beta [20,21,22]. This evidence concerns the gene IL2 and neuroblastoma.